Hims Hers Health Inc (HIMS)vsZoetis Inc (ZTS)
HIMS
Hims Hers Health Inc
$22.02
-8.86%
HEALTHCARE · Cap: $5.67B
ZTS
Zoetis Inc
$115.67
-0.28%
HEALTHCARE · Cap: $52.07B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 303% more annual revenue ($9.47B vs $2.35B). ZTS leads profitability with a 28.2% profit margin vs 5.5%. ZTS appears more attractively valued with a PEG of 1.95. ZTS earns a higher WallStSmart Score of 64/100 (C+).
HIMS
Hold50
out of 100
Grade: D+
ZTS
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-538.6%
Fair Value
$3.47
Current Price
$22.02
$18.55 premium
Margin of Safety
-26.1%
Fair Value
$102.01
Current Price
$115.67
$13.66 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 25 in profit
Revenue surging 28.4% year-over-year
Every $100 of equity generates 66 in profit
Strong operational efficiency at 34.7%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Trading at 9.3x book value
Distress zone — elevated risk
5.5% margin — thin
Operating margin of 2.7%
Expensive relative to growth rate
Trading at 14.8x book value
3.0% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : HIMS
The strongest argument for HIMS centers on Return on Equity, Revenue Growth. Revenue growth of 28.4% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.2% and operating margin at 34.7%.
Bear Case : HIMS
The primary concerns for HIMS are Price/Book, Altman Z-Score, Profit Margin. A P/E of 48.8x leaves little room for execution misses. Debt-to-equity of 2.34 is elevated, increasing financial risk.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
HIMS profiles as a growth stock while ZTS is a value play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.61 — expect wider price swings.
HIMS is growing revenue faster at 28.4% — sustainability is the question.
ZTS generates stronger free cash flow (732M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (64/100 vs 50/100), backed by strong 28.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?